Major medical device maker focused on orthopedic implants, surgical robotics (Mako) and hospital/medsurg equipment.
Major medical device maker focused on orthopedic implants, surgical robotics (Mako) and hospital/medsurg equipment.
Sells implants, instruments and capital equipment to hospitals and surgery centres. A Mako robot is sold as capital equipment and then pulls through the implants used with it, which are tied to Stryker's system. Acquisitions add new device lines each year.
Moat: wide (installed base, switching costs, brand). Mako robotic installed base and surgeon training create strong switching costs in joint replacement.
Headquarters: Kalamazoo, Michigan, USA · Founded: 1941 · Employees: 56,000
Size Stryker (SYK) is a United States Health Care company (Medical Specialties) with a market value of $121B, the 103rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $318.15 on 18 Nov 2026.
Performance Over six months the shares fell 0.8%, against +26.4% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 7.9% over the last twelve months (peer median +8.7%); the operating margin is 24.6% (peer median 20.4%).
Valuation It trades at 19.9× forward earnings against a peer median of 25.4× (8th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.7 points above its cost of capital (8.6% WACC).
Credit Stryker has 20 bonds outstanding ($14.6B), rated BBB+ by the agencies and trading like A at a weighted spread of 74 bp.
Short interest Short interest is 1.8% of the free float (30 Oct 2026).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $26.3B | $25.1B | $22.6B | $20.5B | $18.4B |
| Revenue growth | — | +11% | +10% | +11% | — |
| Gross profit | $16.6B | $15.7B | $14.0B | $12.6B | $11.1B |
| EBITDA | $7.67B | $7.04B | $6.17B | $5.39B | $4.78B |
| Net income | $3.62B | $3.25B | $2.99B | $3.17B | $2.36B |
| Free cash flow | $4.57B | $4.28B | $3.49B | $3.14B | $2.04B |
| Capital expenditure | $873M | $761M | $755M | $575M | $588M |
| Total debt | $15.4B | $16.4B | $14.1B | $13.5B | $13.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
| Zimmer Biomet ZBH | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Smith & Nephew SN..L | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SYK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.5% | +6.1% | 9th lowest of 21 |
| 6-month return | -0.8% | +26.4% | 4th lowest of 21 |
| Distance from 52-week high | -17.8% | -8.0% | 7th lowest of 21 |
| Revenue growth (TTM) | +7.9% | +8.7% | 9th lowest of 21 |
| Operating margin | 24.6% | 20.4% | 8th highest of 21 |
| Forward P/E | 19.9× | 25.4× | 8th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 10.7% | 16.2% | 8th least demanding of 21 |
| Growth delivered (Del g) | +11.8% | +6.4% | 5th highest of 21 |
| Hurdle (Req g minus delivered) | -1.2 pp | +6.1 pp | 5th least demanding of 21 |
| ROIC minus cost of capital | +5.7 pp | +2.7 pp | 8th highest of 21 |
| EV / EBITDA | 17.4× | 19.3× | 9th cheapest of 20 |
| Net debt / EBITDA | 1.6× | 1.9× | 9th least indebted of 20 |
| Bond spread | 74 bp | 75 bp | 6th tightest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Stryker SYK | United States | $121B | -1% | +8% | 25% | 19.9× | 10.7% | +11.8% |
| Medtronic MDT | United States | $129B | +30% | +10% | 20% | 16.8× | 9.1% | +3.8% |
| Intuitive Surgical ISRG | United States | $146B | -6% | +20% | 32% | 34.8× | 29.6% | +18.2% |
| EssilorLuxottica EL.PA | France | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% | +14.6% |
| Danaher DHR | United States | $161B | +34% | +6% | 21% | 25.1× | 20.8% | +2.0% |
| Abbott Laboratories ABT | United States | $181B | +18% | +10% | 14% | 17.9× | 16.5% | +5.1% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Thermo Fisher Scientific TMO | United States | $257B | +53% | +8% | 19% | 25.7× | 21.3% | +6.7% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
Stryker has 20 bonds outstanding with $14.6B face value. The agencies rate it BBB+; its bonds trade like A. Weighted yield 4.89%, a spread of 74 bp over government bonds.